{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:12:13Z","timestamp":1782141133193,"version":"3.54.5"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.gastrohep.2025.502363","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T19:48:54Z","timestamp":1737575334000},"page":"502363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Etrasimod: revisi\u00f3n de la eficacia y las perspectivas terap\u00e9uticas de una nueva terapia oral para el tratamiento de la colitis ulcerosa"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502363_bib0310","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0315","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.disamonth.2019.02.004","article-title":"A comprehensive review and update on ulcerative colitis","volume":"65","author":"Gajendran","year":"2019","journal-title":"Dis Mon"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0320","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance Surgery, and Ileo-anal Pouch Disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0325","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0330","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0335","doi-asserted-by":"crossref","first-page":"212505","DOI":"10.7573\/dic.212505","article-title":"Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study)","volume":"7","author":"Marin-Jimenez","year":"2018","journal-title":"Drugs Context"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502363_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gastrohep.2020.07.001","article-title":"GETECCU 2020 guidelines for the treatment of ulcerative colitis Developed using the GRADE approach","volume":"43","author":"Sicilia","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0345","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0350","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221138160","article-title":"A review of the therapeutic management of ulcerative colitis","volume":"15","author":"Aslam","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0355","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.14309\/ajg.0000000000002145","article-title":"Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety","volume":"118","author":"Chaparro","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0360","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ecco-jcc\/jjab070","article-title":"Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0365","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/apt.14930","article-title":"Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: Results from the ENEIDA registry","volume":"48","author":"Chaparro","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0370","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14740338.2017.1298743","article-title":"The safety of biological pharmacotherapy for the treatment of ulcerative colitis","volume":"16","author":"Fiorino","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0375","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000496739","article-title":"Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus","volume":"37","author":"Danese","year":"2019","journal-title":"Dig Dis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0380","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.crphar.2021.100070","article-title":"Unmet needs in inflammatory bowel disease","volume":"2","author":"Reves","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0385","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis Part 2: Current Management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0390","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/MOG.0000000000000361","article-title":"Surgical rates in the era of biological therapy: Up, down or unchanged?","volume":"33","author":"Olivera","year":"2017","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dld.2022.08.039","article-title":"Colectomy rates in ulcerative colitis: A systematic review and meta-analysis","volume":"55","author":"Dai","year":"2023","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502363_bib0400","doi-asserted-by":"crossref","first-page":"i536","DOI":"10.1093\/ecco-jcc\/jjac190.0537","article-title":"P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: A subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Peyrin-Biroulet","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"Suppl 8","key":"10.1016\/j.gastrohep.2025.502363_bib0405","first-page":"486","volume":"11","author":"Peyrin-Biroulet","year":"2023","journal-title":"MP429 Efficacy and safety of etrasimod in patients with moderate to severe isolated proctitis relative to those with more extensive colitis: Results from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials."},{"key":"10.1016\/j.gastrohep.2025.502363_bib0410","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502363_bib0415","doi-asserted-by":"crossref","first-page":"i709","DOI":"10.1093\/ecco-jcc\/jjac190.0712","article-title":"P582 Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: Post hoc analysis of the phase 3 ELEVATE UC 52 trial","volume":"1","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0420","unstructured":"Velsipity - Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto [consulta Oct 2024] Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20240216161575\/anx_161575_es.pdf"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0425","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/gutjnl-2015-309990","article-title":"The gut microbiota and host health: A new clinical frontier","volume":"65","author":"Marchesi","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0430","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/ijms24021526","article-title":"Pathophysiology of Inflammatory Bowel Disease: Innate Immune System","volume":"24","author":"Saez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0435","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000527422","article-title":"New and Emerging Treatments for Inflammatory Bowel Disease","volume":"104","author":"Higashiyama","year":"2023","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0440","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2022-0255","article-title":"Etrasimod for the treatment of ulcerative colitis","volume":"15","author":"Wils","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0445","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0450","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0455","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1080\/1744666X.2016.1217774","article-title":"Sphingosine-1-phosphate receptor: A novel therapeutic target in ulcerative colitis","volume":"12","author":"Izzo","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0460","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0465","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0470","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1016\/j.gastrohep.2025.502363_bib0475","first-page":"6","volume":"19","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0480","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjae060","article-title":"Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme","volume":"18","author":"Regueiro","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"Suppl 9","key":"10.1016\/j.gastrohep.2025.502363_bib0485","first-page":"6","article-title":"Symptomatic Improvement Observed Within 2 Days of Etrasimod Induction Therapy: Results From ELEVATE UC 52 and ELEVATE UC 12 Studies in Patients With Ulcerative Colitis","volume":"19","author":"Dubinsky","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0490","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.14309\/01.ajg.0000859576.23012.a3","article-title":"Etrasimod 2mg Once Daily as Treatment for Patients With Moderately to Severely Active Ulcerative Colitis: Topline and Subgroup Analysis From ELEVATE UC 52 and ELEVATE UC 12","volume":"117","author":"Feagan","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0495","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ecco-jcc\/jjae079","article-title":"Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0500","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231159452","article-title":"Is there an optimal sequence of biologic therapies for inflammatory bowel disease?","volume":"16","author":"Bressler","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0505","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1136\/gutjnl-2016-311970","article-title":"Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: A population-based study","volume":"66","author":"Hochart","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0510","doi-asserted-by":"crossref","first-page":"100071","DOI":"10.1016\/j.crphar.2021.100071","article-title":"When disease extent is not always a key parameter: Management of refractory ulcerative proctitis","volume":"3","author":"Michalopoulos","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0515","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1136\/gutjnl-2021-324108","article-title":"Drug development for ulcerative proctitis: Current concepts","volume":"70","author":"Caron","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0520","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"Suppl_1","key":"10.1016\/j.gastrohep.2025.502363_bib0525","doi-asserted-by":"crossref","first-page":"i593","DOI":"10.1093\/ecco-jcc\/jjac190.0595","article-title":"Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Armuzzi","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0530","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s12325-023-02457-6","article-title":"Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review","volume":"40","author":"Panaccione","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0535","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2147\/CEOR.S391413","article-title":"Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis","volume":"15","author":"Singh","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0540","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0545","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0550","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/ibd\/izy171","article-title":"Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease","volume":"24","author":"Shmidt","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0555","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis","volume":"17","author":"Peyrin-Biroulet","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0560","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/apt.16802","article-title":"Systematic review with meta-analysis: Loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases","volume":"55","author":"Yang","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0565","unstructured":"Xeljanz - Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del product [consultado Oct 2024] Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2018\/20180625141089\/anx_141089_es.pdf"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0570","unstructured":"Rinvoq - Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del producto [consultado Oct 2024] Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20210820152578\/anx_152578_es.pdf"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0575","unstructured":"Jyseleca - Ficha t\u00e9cnica o resumen de las caracter\u00edsticas del product [consultado Oct 2024] Disponible en: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211112153686\/anx_153686_es.pdf"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0580","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis","volume":"12","author":"Bencardino","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0585","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","article-title":"PK, PD, and interactions: The new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD","volume":"14","author":"Gilardi","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0590","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.18133","article-title":"Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry","volume":"60","author":"Ferreiro-Iglesias","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0595","year":"2019","journal-title":"In: Arena is a wholly owned subsidiary of P, editor."},{"key":"10.1016\/j.gastrohep.2025.502363_bib0600","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1177\/10600280231225770","article-title":"Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis","volume":"58","author":"Choi","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.gastrohep.2025.502363_bib0605","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2025.502363_bib0610","doi-asserted-by":"crossref","first-page":"i536","DOI":"10.1093\/ecco-jcc\/jjac190.0537","article-title":"Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: A subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Peyrin-Biroulet","year":"2023","journal-title":"J Crohns Colitis"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:02:08Z","timestamp":1762264928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570525000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0210570525000287"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502363","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etrasimod: revisi\u00f3n de la eficacia y las perspectivas terap\u00e9uticas de una nueva terapia oral para el tratamiento de la colitis ulcerosa","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"502363"}}